FDA
-
-
-
-
-
-
-
Vanda launches motion sickness drug NEREUS after 40-year gap
-
-
-
-
-
-
-
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) call put ratio 4.2 calls to 1 put into announces FDA approval of Bysanti tablets
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) PT Raised to $7.50 at Jefferies
-
-
-
-
-
-
-
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
-
-
-
-
-
-
-
Vanda Pharmaceuticals reaches dispute resolution framework with FDA
-
-
-
-
-
-
-
Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®
-
325,145 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

